Omeprazole (A2845): Practical Research Guide

Omeprazole, SKU A2845, is a research reagent for experiments involving gastric acid secretion and proton-pump inhibition. The compound is chemically identified as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, with a reported molecular weight of 345.42 and molecular formula C17H19N3O3S. APExBIO identifies it as a potent H+,K+-ATPase inhibitor with dossier-reported activity in both an H+,K+-ATPase assay and a histamine-induced acid-formation assay.

No directly matched paper evidence was supplied for this SKU. Accordingly, the numerical values below are limited to the product dossier, while handling and assay recommendations are presented as workflow guidance rather than as validated experimental outcomes. The Omeprazole product page should be consulted for current lot-specific documentation.

What This Product Solves

In gastric acid secretion research, a common practical problem is selecting an inhibitor with a defined chemical identity, stated potency benchmarks, and usable preparation instructions. A2845 addresses that need as a controlled test article for comparing acid-secretory responses, evaluating assay windows, and testing proton-pump inhibition under experimentally defined conditions.

The dossier reports an IC50 of 5.8 μM for H+,K+-ATPase inhibition and an IC50 of 0.16 μM for histamine-induced acid formation. These values should not be treated as interchangeable. They describe different assay contexts, so the relevant benchmark should be matched to the biological system, activation state, readout, and exposure format used in the experiment. In an antiulcer activity study or peptic ulcer disease model, a change in an acid-related endpoint should also be separated from nonspecific effects on viability, tissue integrity, or assay chemistry.

Because the compound is insoluble in water and ethanol but has a reported solubility of at least 17.27 mg/mL in DMSO, solvent selection is central to reproducibility. A vehicle-matched control is therefore required whenever DMSO is used. The compound is intended for gastric acid-related disorders research and related laboratory models, not for direct clinical translation or therapeutic use.

Protocol Parameters

Use the following parameters as a starting framework. Product-specific values are identified as dossier values; recommendations without a product-reported numeric value are workflow guidance.

• Assay: H+,K+-ATPase inhibition; Value: IC50 5.8 μM; Applicability: biochemical or cell-free proton-pump inhibition assays; Rationale: provides a dossier-reported potency reference for assay planning and result comparison; Basis: product dossier.
• Assay: histamine-induced acid formation; Value: IC50 0.16 μM; Applicability: gastric acid secretion assays using histamine-stimulated acid formation; Rationale: supplies a context-specific benchmark that should be interpreted separately from the H+,K+-ATPase value; Basis: product dossier.
• Material: DMSO stock preparation; Value: solubility ≥17.27 mg/mL in DMSO; Applicability: preparation of concentrated laboratory stocks before dilution into an assay-compatible medium; Rationale: water and ethanol are unsuitable starting solvents according to the dossier; Basis: product dossier.
• Identity: molecular characterization; Value: molecular weight 345.42 g/mol and formula C17H19N3O3S; Applicability: concentration calculations, reagent records, and lot verification; Rationale: reduces transcription and identity errors when preparing experimental solutions; Basis: product dossier.
• Quality: material purity; Value: approximately 98%; Applicability: selection and documentation of research-use material; Rationale: defines the stated quality level but does not replace assay-specific controls or independent identity testing; Basis: product dossier.
• Storage: solid material; Value: −20°C; Applicability: long-term storage of the unopened or appropriately sealed solid; Rationale: follows the stated stability recommendation; Basis: product dossier.
• Preparation practice: working solution handling; Value: no fixed concentration prescribed; Applicability: all assays; Rationale: determine the working level empirically from the assay window, vehicle tolerance, and biological system rather than importing a concentration from an unrelated model; Basis: workflow recommendation.

Workflow Setup and QC Checklist

Stock and working-solution preparation

1. Record the SKU, lot number, stated purity, molecular weight, and formula before weighing or dispensing.
2. Prepare the primary stock in DMSO because the dossier reports insolubility in water and ethanol. Mix until the solution is visibly uniform, and inspect for crystals, haze, or material adhering to the vessel.
3. Dilute the stock into the final assay vehicle using a controlled, consistent sequence. Check the diluted solution again for precipitation, especially when the aqueous phase, salt content, pH, or temperature differs between experiments.
4. Prepare working solutions close to the experiment and avoid retaining solution for long-term storage, because the dossier does not recommend long-term storage of the solution form. Store the solid at −20°C and minimize unnecessary handling cycles.

Assay controls and records

• Include a vehicle control matched to the DMSO content of every test condition. Do not interpret a reduction in acid formation as compound-specific if the vehicle itself changes cell, tissue, or enzyme performance.
• Use an untreated or basal control where appropriate to define the unstimulated signal, and include the relevant stimulation control for histamine-induced acid formation assays.
• Confirm that the assay signal is within its validated working window before comparing inhibition across plates or experiments. Record incubation conditions, order of addition, plate or vessel type, and readout method.
• Document whether the experiment measures direct H+,K+-ATPase activity, stimulated acid formation, tissue-level acid output, or a broader endpoint. This distinction is essential when interpreting the two dossier IC50 values.
• Inspect raw data for precipitation, edge effects, unusual control dispersion, and signal loss unrelated to the intended endpoint. Retain the original calculations and normalization method with the lot record.

For background on target-focused assay framing, see Omeprazole (A2845): Technical Guide for H+,K+-ATPase Inhibition; it complements this article by discussing the relationship between inhibitor use and gastric acid secretion workflows. For practical handling and assay boundaries, see Practical Use of Omeprazole (A2845) in Gastric Acid Research; it provides a related discussion of storage, solubility, and reproducibility considerations.

Common Failure Modes and Fixes

Visible precipitation after dilution

Likely cause: transfer from DMSO into an incompatible aqueous condition, excessive local concentration during mixing, or changes in pH and ionic composition. Fix: standardize the dilution order, mix promptly, inspect the final preparation, and reject conditions in which the test article is visibly lost from solution. Keep the vehicle composition consistent across all controls.

Inconsistent potency between runs

Likely cause: comparing a biochemical IC50 with a histamine-induced acid-formation IC50, changing the stimulation protocol, or using different exposure and readout conditions. Fix: define the assay context before setting the test design and use the matching dossier benchmark only as a reference point. Do not combine values from different assay formats into a single potency curve.

Reduced activity after stock storage

Likely cause: prolonged storage of solution, repeated handling, or unrecorded changes in appearance. Fix: maintain the material as a solid at −20°C, prepare solution close to use, and record preparation date, solvent, appearance, and lot number. If a result is anomalous, compare a newly prepared solution with the retained workflow record rather than assuming biological resistance.

Vehicle-associated signal changes

Likely cause: unequal DMSO content between treated and control wells or inadequate vehicle tolerance testing. Fix: normalize the vehicle across conditions and verify that the vehicle-only control remains within the predefined assay acceptance range.

Scope and Limitations

A2845 is appropriate for scientific investigations of gastric acid secretion, H+,K+-ATPase inhibition, antiulcer activity, and selected peptic ulcer disease model workflows. The supplied dossier does not establish a universal dose, exposure time, selectivity profile across unrelated ATPases, in vivo efficacy, pharmacokinetics, toxicity profile, or performance in every gastric acid-related disorders model. Those variables must be established separately for each system.

The reported purity is approximately 98%, which supports research use but does not eliminate the need for lot documentation and assay controls. No directly matched paper evidence is available in the supplied materials, so this article does not assign an expected effect size or claim a validated outcome in cells, tissues, animals, or patients. The product is strictly for scientific research and is not intended for diagnostic, medical, or therapeutic use.

Conclusion

Omeprazole A2845 can provide a practical, dossier-defined tool for gastric acid secretion research when assay context, solvent compatibility, and storage are controlled. Use the 5.8 μM and 0.16 μM values only within their respective assay contexts, prepare stocks in DMSO, maintain vehicle-matched controls, store the solid at −20°C, and treat all broader biological conclusions as system-specific findings requiring independent validation.